For the Inventor, By the Inventor

Enter inventor name

Tunbridge, VT, United States of America

Michael B Sporn

This inventor holds 31 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 2 EPO patents, primarily in Synthetic Triterpenoids. Top assignees: Dartmouth College, Reata Pharmaceuticals, Inc., Triterpenoid Therapeutics, Inc.. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael B Sporn. Retrieved from https://idiyas.com/inventor/michael-b-sporn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 5)

% Patents Active = 64.5

CIPO Patents = 3

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 3.5

ph-index = 19

Forward Citations = 1,231(Granted Patents)

Location History:

Hanover, NH (US) (2011)
Turnbridge, VT (US) (2016 - 2017)
Tunbridge, VT (US) (2001 - 2019)

Company Filing History:

Dartmouth College

Reata Pharmaceuticals, Inc.

Triterpenoid Therapeutics, Inc.

4. 2 out of 5,633

The University of Texas System

Osteoscreen, Inc.

6. 1 out of 1,496

Rutgers, The State University of New Jersey

7. 1 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

8. 1 out of 16,008

University of California

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Synthetic Triterpenoids

Enzyme Inhibition

NLRP3 Inflammasome

Therapeutic Compounds

Pyridyl Analogs

Tricyclic-Bis-Enones

CDDO-Compounds

Stem Cell Modulation

Bone Growth

Betulinic Acid Derivatives

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12649763 - Analogs of CDDO-2P-Im and CDDO-3P-Im (2026-06-09),

2. 12551562 - METHODS AND COMPOSITIONS FOR IRREVERSIBLE ENZYME INHIBITION (2026-02-17),

3. 12370202 - Methods and compositions for inhibiting the NLRP3 inflammasome and/or LON protease (2025-07-29),

4. 10501420 - Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole (2019-12-10),

5. 10189791 - Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole (2019-01-29),

6. 9896475 - Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole (2018-02-20),

7. 9757359 - Synthetic triterpenoids and methods of use in the treatment of disease (2017-09-12),

8. 9539287 - Triterpenoids and compositions containing the same (2017-01-10),

9. 9290455 - CDDO-Me amino acid conjugates and methods of use (2016-03-22),

10. 9278913 - Therapeutic compounds and methods of use (2016-03-08),

11. 9205113 - Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression (2015-12-08),

12. 8921419 - Triterpenoids and compositions containing the same (2014-12-30),

13. 8921340 - Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions (2014-12-30),

14. 8778990 - Betulinic acid derivatives and methods of use thereof (2014-07-15),

15. 8586775 - Therapeutic compounds and methods of use (2013-11-19),

Title: The Innovative Contributions of Michael B. Sporn

Introduction: Michael B. Sporn, based in Tunbridge, Vermont, is an accomplished inventor with a notable array of 28 patents to his name. His work primarily focuses on developing novel pharmaceutical compositions, showcasing his expertise in medicinal chemistry and innovation in drug formulation.

Latest Patents: Among his latest noteworthy patents are the "Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole" which outlines innovative pharmaceutical compositions. This invention represents a significant advancement in the field, providing new options for therapeutic applications and detailing the composition and potential uses of these pyridyl analogs.

Career Highlights: Throughout his career, Sporn has contributed significantly to the biomedical field. His experience with prestigious institutions such as Dartmouth College and Reata Pharmaceuticals, Inc. has allowed him to advance his research and enhance his contributions to the field of pharmaceuticals. His inventions have become critical in the development of new medications, demonstrating his commitment to improving healthcare through innovation.

Collaborations: Sporn has collaborated with distinguished colleagues including Gordon W. Gribble and Tadashi Honda. These professional relationships have not only enriched his research but have also led to a sharing of ideas that spur further innovations within their respective fields.

Conclusion: Michael B. Sporn is a passionate inventor whose work continues to impact the pharmaceutical industry profoundly. With his impressive patent portfolio and cooperative spirit, he remains a valuable asset to the world of medicinal research and innovation. His ongoing projects promise to lead to even more groundbreaking advancements in health solutions.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…